Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that 44% of hirsute women undergoing cyproterone acetate treatment experienced impaired sexual enjoyment, highlighting the need to inform patients about potential side effects.

This study found that men experiencing persistent sexual side effects from finasteride also commonly report depressive symptoms and suicidal thoughts.

This review describes techniques to manage intraoperative floppy iris syndrome linked to alpha-1 blocker use in cataract surgery, highlighting the need for patient disclosure of medication use but reports no new clinical results.

In this case report, a 63-year-old man with an abnormally enlarged bladder holding 15 liters of urine was asymptomatic, emphasizing that chronic urinary retention can occur without symptoms and requires timely intervention to avoid complications.

This study suggests that circulating androgens produced by the testes have limited clinical relevance to major depressive disorder in adult men, but certain androgens may be linked to specific MDD symptoms.

This study found that transdermal testosterone significantly increased the frequency of satisfactory sexual events in women experiencing SSRI/SNRI-related loss of libido, but did not improve overall sexual self-rating scores.

In this case report, an 18-year-old Vietnamese female with primary amenorrhea and normal female phenotype was most likely diagnosed with müllerian agenesis, highlighting its association with embryologic underdevelopment of the müllerian duct.

This case report describes a 63-year-old woman with hyperandrogenism due to an ectopic adrenal gland adenoma on the ovaries, successfully treated with bilateral salpingo-oophorectomy.

This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

This editorial comment discusses combination therapy for benign prostatic hyperplasia but presents no new research findings.

This case report highlights a persistent gynecomastia in a young man following low-dose finasteride, suggesting that the incidence may be underreported and calls for patient counseling and early intervention.

In this study, dutasteride 1 mg daily reduced heavy drinking days and drinks per week among treatment-seeking men, particularly benefiting those with high baseline drinking to cope motives.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.

This case series suggests that EE/CMA 0.03mg/2mg may help manage dermatological disorders related to androgen excess, as evidenced by symptomatic improvements in the four patients treated.

This article highlights various research studies in adult urology from the July 2013 issue of the Journal of Urology but does not report new research findings itself.

This pilot study found that using skin patting and iontophoresis to deliver a 6% dutasteride gel led to significant improvements in hair density and shaft diameter in men and postmenopausal women with treatment-resistant androgenetic alopecia, with no reported adverse events.

This study found that patients treated with dutasteride were significantly less likely to experience acute urinary retention and prostate-related surgeries compared to those treated with finasteride.

This study explored the effects of MOTILIPERM on infertility in a rat model with varicocele and oxidative stress, reporting its potential therapeutic efficacy.

This observational study in Bogotá found that skin issues like acne and androgenetic alopecia are common among adults with gender dysphoria on hormone therapy, emphasizing the need for dermatological care as part of comprehensive treatment.

This study reports that prostate volume, operation time, resected tissue weight, and smoking increase risks of blood loss and fluid absorption during PK-TURP, while finasteride treatment and surgeon experience may reduce these risks.

This review discusses the risk of central nervous side effects, such as dementia and depression, from drugs used to treat lower urinary symptoms related to benign prostatic hyperplasia, and highlights inconsistent evidence across different medications.

This case report describes a rare instance of labial hair tourniquet syndrome in a 10-year-old girl, emphasizing the importance of considering this condition in the differential diagnosis of vulvar lesions.

This source reports that testosterone therapy may mildly improve sexual desire in women with sexual dysfunction but lacks long-term safety data and cannot be widely recommended, as no formulations are approved for women in most countries.

This review concludes that the global literature supports the efficacy and safety of lipidosterolic extract of Serenoa repens in treating lower urinary tract symptoms, comparable to alpha-blockers and 5α-reductase inhibitors.

This study found that free testosterone levels were 29% higher with the levonorgestrel implant than with the DMPA injection, which may impact sexual function, mood, and side effects like acne.

This case study reported a unique instance of a benign adrenal adenoma co-secreting cortisol and DHEA-S, which initially mimicked PCOS symptoms. Surgical removal resulted in significant clinical improvement, confirming the diagnosis of cyclic adrenal Cushing's syndrome.

This review reports that 5-alpha reductase inhibitors, used to treat androgenic alopecia, may adversely affect sperm count, sexual function, and hormones in a subset of patients.

An 84-year-old man got a rare scalp condition from using imiquimod cream, which was cured with systemic steroids.

This study found no significant differences in plasma DHEA-S and total testosterone levels between female patients with androgenetic alopecia and normal controls, regardless of clinical type or hyperandrogenic symptoms.